首页> 外国专利> PERIPHERICAL TISSUE SAMPLE CONTAINING CELLS EXPRESSING THE 5HTR2C AND/OR ADARS AS MARKERS OF THE ALTERATION OF THE MECHANISM OF THE 5HTR2C MRNA EDITING AND ITS APPLICATIONS

PERIPHERICAL TISSUE SAMPLE CONTAINING CELLS EXPRESSING THE 5HTR2C AND/OR ADARS AS MARKERS OF THE ALTERATION OF THE MECHANISM OF THE 5HTR2C MRNA EDITING AND ITS APPLICATIONS

机译:包含表达5HTR2C和/或ADAS的细胞的外周组织样品,作为改变5HTR2C MRNA编辑机制的标志及其应用

摘要

The present invention relates to an in vitro method for predicting a pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing, particularly the serotonin 2C receptor (5HTR2C), in a patient from a peripherical tissue sample containing cells expressing said mRNA, such as the 5HTR2C mRNA, and/or adenosine deaminases acting on RNA (ADARs), such as skin and/or blood tissue sample. The present invention further comprises a method for identifying if an agent is capable of in vivo modifying the editing of the 5HTR2C mRNA in brain tissue or to control the efficiency of a drug intended to prevent or to treat a pathology related to an alteration of the mechanism of the 5HTR2C mRNA editing brain tissue, these methods comprising the implementation of said peripherical tissue markers. In a particular aspect, the present invention relates to such methods wherein the 5HTR2C mRNA editing rate or profile, when it is necessary, is determined by a single strand conformation polymorphism (SSCP) method after amplification by a PCR, preferably by a nested PCR, of the specific mRNA fragment containing the edition sites, making it possible, under given analytical conditions, to obtain the editing rate and/or profile of this edited 5HTR2C mRNA from said peripherical tissue. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR.
机译:本发明涉及一种从外周组织样品中预测与ADAR依赖性A至I mRNA编辑,特别是5-羟色胺2C受体(5HTR2C)的ADAR依赖的mRNA编辑的机制改变有关的病理学的体外方法。含有表达所述mRNA的细胞(例如5HTR2C mRNA)和/或作用于RNA(ADAR)的腺苷脱氨酶,例如皮肤和/或血液组织样品。本发明进一步包括一种方法,该方法用于鉴定一种药物是否能够体内修饰脑组织中5HTR2C mRNA的编辑或控制旨在预防或治疗与该机制改变有关的病理的药物的效率。在5HTR2C mRNA编辑脑组织中,这些方法包括实施所述外周组织标志物。在一个特定的方面,本发明涉及这样的方法,其中5HTR2C mRNA编辑速率或概况在必要时通过PCR,优选通过巢式PCR扩增后,通过单链构象多态性(SSCP)方法确定,含有编辑位点的特定mRNA片段的表达,使得在给定的分析条件下有可能从所述周围组织获得该编辑的5HTR2C mRNA的编辑率和/或谱。最后,本发明涉及在所述巢式PCR中实施的特定核酸引物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号